Drugs / Tazbentetol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07325591 | Mar 2026 → Dec 2027 expected | amyotrophic lateral sclerosis | Spinogenix | Not yet recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07088159 | — | amyotrophic lateral sclerosis | Spinogenix | Available | No outcome recorded |
Press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tazbentetol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07088159 ↗ |
| Route | Oral | “300 mg Tazbentetol will taken by mouth once daily.” NCT07088159 ↗ |